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Abstract 16 
Canine lymphoma is a multifaceted disease encompassing numerous entities with different 17 
prognosis. Objective assessment of the proliferation rate is of great importance from both 18 
pathological and clinical point of view. Different methods have been described in the literature to 19 
assess it, including evaluation of Ki67 expression on fresh lymph node (LN) aspirates by flow 20 
cytometry (FC). This test has a high accuracy in discriminating low- and high-grade lymphomas, 21 
and provides prognostic information among high-grade B-cell lymphomas. DNA content analysis is 22 
less expensive and suitable for preserved samples. We describe DNA-content analysis on LN 23 
aspirates from 112 dogs with lymphoma. Based on our results, S-phase fraction (SPF) accurately 24 
discriminates between low and high-grade lymphomas, being 3.15% the best discriminating cut-off. 25 
SPF values strongly correlate with Ki67 expression assessed by FC. Survival analyses were 26 
restricted to 33 dogs with high-grade B-cell lymphoma receiving a standardized multi-agent 27 
chemotherapy, but no significant result for SPF was obtained. We also describe a subset of 28 
aneuploid cases and their respective follow-up. We conclude that DNA content analysis may be 29 
combined with morphological examination of LN aspirates to improve the objectivity in lymphoma 30 
subtype classification in dogs. Further studies are needed to assess possible prognostic role of both 31 
SPF and ploidy status within specific lymphoma subtypes in the canine population. 32 
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Introduction 37 
The definition of neoplasia has evolved during the past decades, as new concepts were taken into 38 
account, such as sustenance of the proliferative signalling, evasion of growth suppression, 39 
resistance to cell death, replicative immortality and induction of angiogenesis (Hanahan and 40 
Weinberg, 2000; Vincent, 1987; Willis, 1952). However, uncontrolled proliferation continues to be 41 
considered a hallmark of cancer cells (Fouad and Aanei, 2017; Golias et al., 2004; Hanahan and 42 
Weinberg, 2000, 2011; Kaufman et al., 2007). Indeed, dysregulation of the cell cycle is a major 43 
contributor to the pathogenesis of neoplasms (Dictor et al., 1999; Wiman and Zhivotovsky, 2017).  44 
The DNA content of the cells varies with progression in the cell cycle: cells in G0 and G1 phases 45 
maintain two complete sets of chromosome (diploid cells, 2n); during the S-phase, the DNA 46 
amount progressively increases until duplication; cells in G2 and M phases are tetraploid (4n). 47 
Thus, cell distribution within the phases of the cell cycle can be revealed analysing the DNA 48 
content of the cellular population. This is generally achieved via flow cytometry (FC), using 49 
fluorescent DNA dyes (Darzynkiewicz et al., 2017; Ormerod et al., 1998; Wilkerson 2012) and 50 
particularly assessing the fraction of cells in S-phase (SPF). As replicating DNA is more prone to 51 
carcinogen attacks, S-phase is a crucial step of the cell cycle in the process of neoplastic 52 
transformation and development (Kaufman et al., 2007). 53 
In dogs, DNA content and ploidy have been described for transitional cell carcinomas of urinary 54 
bladder, mast cell tumours, melanomas, mammary tumours, osteosarcomas and lymphomas (Ayl et 55 
al., 1992; Bolon et al., 1990; Clemo et al., 1994; Fox et al., 1990; Hellmen et al., 1993; Teske et al., 56 
1993). 57 
In particular, Teske and colleagues investigated the DNA content and ploidy status in canine 58 
lymphoma, but failed to detect any correlation with lymphoma subtype or phenotype, and with 59 
survival (Teske et al., 1993). Canine lymphoma is a heterogeneous disease and encompasses 60 
numerous entities with different clinical presentation, behaviour and follow up (Aresu et al., 2015; 61 
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Valli et al 2013). The study by Teske and colleagues dates back to 1993 and was based on the 62 
Working Formulation (WF) classification scheme. From then on, other classification schemes have 63 
been introduced for canine lymphoma. Based on a recent review, the WF classification appears to 64 
be of poor clinical and prognostic interest, differently from both the World Health Organization 65 
(WHO) histopathological scheme and the updated Kiel cytological scheme (Sayag et al., 2018). 66 
Still, morphological evaluation alone remains operator-dependent, and the inclusion of other 67 
objective data can contribute to improve the intra- and inter-observer reproducibility (Teske and van 68 
Heerde, 1996). 69 
The combined use of cytology, immunophenotype and FC assessment of Ki67 expression has been 70 
recently proposed as a reliable tool for the classification of canine lymphomas (Poggi et al., 2015). 71 
Ki67 FC quantification has also a prognostic value in dogs with high-grade B-cell lymphomas 72 
(Poggi et al., 2017). Unfortunately, this technique has been applied only on fresh samples (within 73 
24 hours from sampling) in the dog (Poggi et al., 2015). In addition, changes >20% in Ki67 74 
expression are reported in human blood stored for 72-96 hours before analysis, even if collected in 75 
tubes containing a cell preservative commonly used for FC analysis (Sun et al., 2016). On the 76 
contrary, preserved or archive material is suitable for DNA content analysis (Ormerod et al., 1998). 77 
In addition, this technique is less expensive, requiring only fluorescent DNA dyes, whereas 78 
monoclonal antibodies and permeabilizing solutions are needed to assess Ki67 expression via FC 79 
(Kim and Sederstrom, 2015). 80 
Aim of the present study was to assess the diagnostic and prognostic role of DNA content analysis 81 
in canine lymphomas. In particular, we describe: 1) the S-phase fraction (SPF) in different 82 
lymphoma subtypes; 2) the correlation of SPF with other proliferation rate markers (Ki67); 3) the 83 
prevalence of aneuploidy and the follow up of aneuploid cases; and 4) the possible prognostic role 84 
of SPF among dogs with high-grade B-cell lymphoma undergoing a standardized treatment 85 
regimen. 86 
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 87 
Materials and methods 88 
Case selection and classification 89 
The FC database of the Veterinary Teaching Hospital of the University of Turin was retrospectively 90 
investigated from January 2011 to September 2014. All consecutive cases fulfilling the following 91 
inclusion criteria were extrapolated: 1) a final diagnosis of nodal lymphoma based on clinical 92 
presentation, complete blood count, cytological and FC examination of an enlarged peripheral 93 
lymph node (LN), 2) availability of a LN cytological sample for review, and 3) availability of FC 94 
immunophenotype and DNA content analysis on LN. Dogs treated with corticosteroids or 95 
chemotherapy agents prior to FC analysis were excluded as well as samples of poor quality for 96 
DNA content analysis: Background Aggregates and Debris (BAD) >20% and/or G0/G1 peak 97 
Coefficient of Variation (CV) >8%  (Ormerod et al., 1998). 98 
All dogs were privately owned and sampled for diagnostic purposes with a written informed 99 
consent of the owners. Thus, a specific formal approval of the Institution Committee for Animal 100 
Care of the University of Turin was not required. 101 
Cytological samples were reviewed by a single operator and cases were classified according to the 102 
updated Kiel classification scheme (Fournel-Fleury et al., 1997). LN aspirates collected into tubes 103 
containing RPMI-1640 or saline solution were processed for FC immunophenotyping within 24 104 
hours from sampling as previously described (Gelain et al., 2008). Different combinations of the 105 
following monoclonal antibodies were used for this aim: CD45 (clone YKIX716.13), CD3 (clone 106 
CA17.2A12), CD5 (clone YKIX322.3), CD4 (clone YKIX302.9), CD8 (clone YCATE55.9), CD21 107 
(clone CA2.1D6), CD79b (clone AT107-2), CD34 (clone 1H6). All antibodies were provided by 108 
Serotec (Oxford, UK) except CD34 (BD Becton Dickinson; San Josè, CA, USA). Ki67 expression 109 
was determined as previously described (Poggi et al., 2015). All samples were acquired with a BD 110 
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Accuri C6 (BD Becton Dickinson) and analysed with the specific software CFlow Plus (BD Becton 111 
Dickinson).  112 
For high-grade B-cell lymphoma and aneuploid tumours cases, the referring veterinarians were 113 
contacted to retrieve signalment data (including breed, sex and age at diagnosis), as well as clinical 114 
stage and substage according to the WHO staging system (Owen, 1980), and follow up data. 115 
DNA content analysis 116 
LN aspirates were fixed in 70% ethanol and stored at -20°C for a minimum of 2 hours, until 117 
analysis for DNA content. Immediately prior to processing, all samples were washed twice in PBS 118 
1x and the supernatant was finally discarded. 500µl of a staining solution containing propidium 119 
iodide (50 µg/ml) and Ribonuclease (RNase, 0.2mg/ml) were added to the cell pellet (1x106 120 
cells/tube), incubated for 15 minutes, and then acquired with the BD Accuri C6 flow cytometer. 121 
Nucleated cells from peripheral blood of a healthy dog, obtained by RBC lysis with a solution 122 
containing 8% ammonium chloride, fixed in 70% ethanol and stored at -20°C were processed along 123 
with each neoplastic LN sample, to serve as a normal diploid control. 124 
Analyses were performed with a dedicated software (Multicycle for Windows, in FCS Express). 125 
Data were represented by a histogram with the fluorescence intensity on X-axis, and the number of 126 
cells on Y-axis. The SPF was calculated as the area under the curve between G0/G1 and G2/M 127 
peak.  128 
Cases were considered aneuploid if two G0/G1 peaks were identified. When a single peak was 129 
present or the diploid peak was not clearly recognizable, an aliquot of the control tube was added. 130 
The DNA index (DI) was calculated as the ratio between the mean channel number of the G0/G1 131 
extra-peak and the mean channel number of the G0/G1 diploid peak. 132 
Statistical analysis 133 
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All statistical analyses were performed with a specific software (SPSS v21.0, SPSS Inc, Chicago, 134 
USA) and significance was set at p≤0.05 for all tests. 135 
Many cytological subtypes were poorly represented or absent in our case series. Thus, for statistical 136 
purposes, cases were re-classified based on phenotype and cytological malignancy grade in: high-137 
grade B-cell, high-grade T-cell, low-grade B-cell and low-grade T-cell subtypes. 138 
A Shapiro-Wilk test was performed to assess whether SPF data were normally distributed within 139 
groups. A Levene’s test was performed to test the homoscedasticity assumption. Thereafter, 140 
possible SPF variations among lymphoma subtypes were assessed with a Brown-Forsythe ANOVA 141 
test. Post-hoc analyses were performed with a Dunnett test. 142 
A Receiving Operator Curve (ROC) was drawn to select the SPF cut-off best discriminating 143 
between low- and high-grade lymphomas, based on the best compromise between sensitivity and 144 
specificity. 145 
The Pearson’s correlation coefficient between SPF and Ki67 expression was calculated. The 146 
equation of the regression line was used to identify the SPF values corresponding to 20% and 40% 147 
Ki67 expression, respectively, as these values were proved to be of prognostic impact in dogs with 148 
high-grade B cell lymphoma (Poggi et al., 2017). These SPF cut-offs were then used for survival 149 
analyses. 150 
Survival analyses were restricted to dogs with high-grade B-cell lymphoma treated with a 25-weeks 151 
Winsconsin-Madison chemotherapy protocol (UW-25) (Garrett et al., 2002), in order to reduce the 152 
bias linked to inclusion of different lymphoma subtypes and treatment regimens. 153 
Follow up data were also recorded for aneuploid cases, although survival analyses were not 154 
attempted because of the low number of cases and the wide spectrum of lymphoma subtypes and 155 
treatment regimens adopted. 156 
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According to the official guidelines (Vail et al., 2010), complete response (CR) was defined as 157 
disappearance of all evidence of disease in target lesions, disease-free survival (DFS) as time from 158 
documentation of CR and relapse, and lymphoma-specific survival (LSS) as time from initiation of 159 
treatment and death for lymphoma. Dogs lost to follow up, still in CR at data analysis closure, or 160 
dead for lymphoma-unrelated causes before lymphoma relapse were censored for DFS analyses. 161 
Dogs lost to follow up, still alive at data analysis closure, or dead for lymphoma-unrelated causes 162 
were censored for LSS analysis. 163 
Univariate Cox’s proportional hazard regression analysis was performed, to assess possible 164 
influence on DFS and LSS of the following variables: breed (pure or mixed), sex (male or female), 165 
age (< or ≥8 years), stage (I to V), substage (a or b), Ki67 expression (≤20%, between 20% and 166 
40%, >40%), SPF (≤5.90%, between 5.90% and 11.72%, >11.72%), obtainment of CR (yes or not). 167 
Variables with P-value ≤0.30 were then included in a backward elimination multivariate analysis. In 168 
addition, Kaplan Meier curves were drawn and compared with log-rank test to assess possible 169 
variations in median DFS and LSS according to the aforementioned variables. 170 
Results 171 
Overall, DNA content analysis was performed in 124 cases. Among them, 12 (9.7%) were of poor 172 
quality (BAD >20% and/or G0/G1 peak CV >8%). Thus, 112 cases were finally included in the 173 
study. 174 
Concerning lymphoma subtype, 41 (36.6%) cases were centroblastic polymorphic B-cell, 16 175 
(14.3%) centroblastic monomorphic B-cell, 10 (8.9%) small clear T-cell, 9 (8.0%) immunoblastic 176 
B-cell, 9 (8.0%) pleomorphic mixed small and large T-cell, 6 (5.4%) macronucleolated medium-177 
sized B-cell, 6 (5.4%) pleomorphic large T-cell,  4 (3.6%) lymphoblastic B-cell, 4 (3.6%) 178 
lymphoblastic T-cell, 3 (2.7%) pleomorphic small T-cell,  and 1 (0.9%) each of the following: 179 
plasmacytoid B-cell, plasmacytoid T-cell, prolymphocytic B-cell and prolymphocytic T-cell. Thus, 180 
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71 (63.4%) dogs had a high-grade B-cell lymphoma, 20 (17.9%) had a high-grade T-cell 181 
lymphoma, 14 (12.5%) a low-grade T-cell lymphoma, and 7 (6.2) a low-grade B-cell lymphoma. 182 
S-phase fraction 183 
Overall mean SPF was 9.36±7.81% (median 8.50%; min-max 0.2-46.4%). In particular, high-grade 184 
B-cell lymphomas had a mean SPF of 11.35±8.11% (median 9.30%; min-max 1.3-46.4%), high-185 
grade T-cell lymphomas a mean SPF of 10.95±4.60% (median 10.70%; min-max 3.4-21.5%), low-186 
grade T-cell lymphomas a mean SPF of 1.08±0.94% (median 0.85%; min-max 0.2-3.1%) and low-187 
grade B-cell lymphomas a mean SPF of 1.30±0.77% (median 1.30%; min-max 0.6-2.8%). SPF 188 
values for specific cytological subtypes are listed in table 1. 189 
SPF variation among lymphoma subgroups was statistically significant (p<0.001). In particular, 190 
SPF was higher in high-grade B-cell than in low-grade B- and T-cell lymphomas and higher in 191 
high-grade T-cell than in low-grade B- and T-cell lymphomas (p<0.001 for all comparisons). 192 
Differences between high-grade B- and T-cell lymphomas and between low-grade B- and T-cell 193 
lymphomas were not significant (p>0.05) (Fig.1). 194 
ROC curve identified a high accuracy of SPF in discriminating between low- and high-grade 195 
lymphomas (area under the curve AUC=0.996), being 3.15% the best cut-off (sensitivity 97.8%, 196 
specificity 100.0%) to identify high-grade lymphomas. 197 
Correlation between SPF and Ki67 198 
Ki67 expression was assessed in 100 cases, with a mean overall value of 31.66±18.69% (median 199 
30.00%; min-max 1.00-71.00%). A strong correlation between Ki67 expression and SPF was 200 
detected (p<0.001, r=0.753). The equation was: SPF=0.075+0.291*Ki67. Thus, the SPF cut-offs 201 
corresponding to 20% and 40% Ki67 expression were 5.90% and 11.72%, respectively. These cut-202 
offs were then used in the survival analyses. 203 
Ploidy 204 
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Among the 112 cases included, 105 (93.8%) were diploid and 7 (6.2%) aneuploid. These included 3 205 
(42.9%) high-grade B-cell lymphomas (2 immunoblastic and 1 centroblastic monomorphic), 3 206 
(42.9%) high-grade T-cell lymphomas (2 pleomorphic mixed small and large and 1 lymphoblastic) 207 
and 1 (14.3%) low-grade T-cell lymphoma (pleomorphic small cells). 208 
Mean DI of aneuploid cases was 1.20±0.07 (median 1.18; min-max 1.14-1.36). Five (71.4%) cases 209 
had DI<1.20 and were subclassified as near-diploid (Bauer et al 1993). A lymphoblastic T-cell 210 
lymphoma had a DI=1.21, and a centroblastic monomorphic B-cell lymphoma had a DI=1.36. 211 
Breed was not reported in one case; the other dogs represented 6 different pure breeds. Three 212 
(42.9%) were females (1 spayed) and 4 (57.1%) males (1 neutered). Mean age at diagnosis was 213 
10.8±2.3 years (median 11 years; min-max 7-14 years) but was not reported in one case. 214 
Follow up data were available for the 5 near-diploid cases. One dog with high-grade B-cell 215 
lymphoma was treated with corticosteroid alone and was still alive after 58 days from the diagnosis; 216 
the other one entered the UW-25 chemotherapy protocol but died for lymphoma-unrelated causes 217 
after 45 days from the diagnosis. One dog with high-grade T-cell lymphoma was treated with 218 
single-agent chemotherapy and died for lymphoma on day 20; the other one entered the UW-25 219 
chemotherapy protocol, had a DFS of 56 days and died for lymphoma on day 70. The dog with low-220 
grade T-cell lymphoma received chlorambucile and prednisone, did not achieve CR and died for 221 
lymphoma on day 111. 222 
Survival analyses 223 
Follow up data were available for 51 dogs with high-grade B-cell lymphoma. Among them, 8 224 
(15.7%) received prednisone alone, 6 (11.8%) no treatment, and 4 (7.8%) single-agent 225 
chemotherapy. Thus, survival analyses were restricted to 33 dogs that were treated with the UW-25 226 
chemotherapy protocol. 227 
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Breed was known for 32 cases, including 21 (65.6%) pure-breed dogs of 17 different breeds and 11 228 
(34.4%) mixed-breed. Sex was known for 32 cases, with 16 (50%) intact males and 16 (50%) 229 
females (7 spayed). Among 29 dogs whose age was known, 13 (44.8%) were <8 years old and 16 230 
(55.2%) were ≥8 years old. Twenty-nine dogs underwent full staging: 3 (10.3%) were classified as 231 
stage IV disease and 26 (89.7%) as stage V. Eight (24.2%) dogs were in substage a and 25 (75.8%) 232 
in substage b. Ki67 expression had been tested in 29 dogs: it was ≤20% in 5 (17.2%) dogs, between 233 
20% and 40% in 16 (55.2%), and >40% in 8 (27.6%). SPF was ≤5.90% in 6 (18.2%) dogs out of 33, 234 
between 5.90% and 11.72% in 19 (57.6%) dogs and >11.72% in 8 (24.2%) dogs. All dogs but one 235 
were diploid: the aneuploid case had a DI of 1.18. Nineteen (59.4%) dogs achieved CR and 13 236 
(40.6%) did not; this information was not available for 1 dog. 237 
None of the 19 dogs that achieved CR was censored for DFS analysis. Overall median DFS was 238 
235 days (range 14-747 days). Among the investigated variables, significant results were obtained 239 
only for sex and Ki67 expression. In particular, median DFS was 349 days (range 159-747 days) for 240 
female dogs and 102 days (range 14-508 days) for male dogs: significant results were obtained with 241 
univariate and multivariate Cox’s analysis (p=0.020 and p=0.022, respectively) as well as with log-242 
rank test (p=0.014). Median DFS was 159 days (range 159-200 days) for dogs with low Ki67 243 
expression, 329 days (range 14-747 days) for dogs with intermediate Ki67 expression, and 75 days 244 
(range 70-349 days) for dogs with high Ki67 expression significant results were obtained with 245 
multivariate Cox’s analysis (p=0.039) and with log-rank test (p=0.042); p-value for univariate 246 
analysis was 0.063. 247 
Ten (30.3%) dogs were censored for LSS analysis: 7 were still alive at data analysis closure with a 248 
median follow-up of 528 days (range 28-872 days), whereas 3 died for lymphoma-unrelated causes 249 
after 34, 45 and 210 days, respectively. Overall median LSS was 365 days (range 15-1086 days). 250 
Among the investigated variables, significant results were obtained only by the achievement of CR 251 
(p<0.001 for univariate Cox’s analysis and log-rank test, and p=0.001 for multivariate analysis): 252 
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median LSS was 531 days (range 34-1086 days) for dogs that achieved CR and 45 days (range 15-253 
320 days) for dogs that did not. A difference in the median LSS was also noted among the three 254 
Ki67 expression groups, although it did not reach statistical significance (p=0.099 for univariate 255 
Cox’s analysis and p=0.081 for log-rank test): median LSS was 240 days (range 34-365 days) for 256 
dogs with low Ki67 expression, 728 days (range 28-1086 days) for dogs with intermediate Ki67 257 
expression, and 150 days (range 15-872 days) for dogs with high Ki67 expression.  258 
The datasets generated during and/or analysed during the current study are available from the 259 
corresponding author on reasonable request 260 
Discussion 261 
DNA content analysis has been used in veterinary medicine to characterize the proliferative activity 262 
of different neoplasms (Ayl et al., 1992; Bolon et al., 1990; Clemo et al., 1994; Fox et al., 1990; 263 
Hellmen et al., 1993; Teske et al., 1993). In the present study, we describe the variation in SPF 264 
among different lymphoma subtypes in dogs, and its diagnostic and prognostic implications. We 265 
also describe a subset of aneuploid cases. 266 
Identification of the malignancy grade is a crucial step in the diagnostic workup for dogs with 267 
lymphoma because of its prognostic impact: high-grade lymphomas have a more aggressive clinical 268 
behaviour than low-grade indolent lymphomas (Aresu et al., 2015; Ponce et al., 2004; Valli et al., 269 
2013). Indeed, assessment of the mitotic index is required by all morphological classification 270 
schemes (either cytological or histopathological) (Fournel-Fleury et al., 1997; Greenle et al., 1990; 271 
Teske et al., 1994). Morphological assessment is somewhat operator-dependent, and a slight level 272 
of intra- and inter-observer disagreement may occur, even among the most experienced and 273 
specialized pathologists (Valli et al., 2011). Thus, tools that more objectively estimate the 274 
proliferation rate in histopathological sections of canine lymphomas have been introduced decades 275 
ago, such as AgNOR count and Ki67 expression (Kiupel et al., 1998, 1999; Phillips et al., 2000). 276 
Unfortunately, many veterinary oncologists do not include histopathological examination in their 277 
13 
 
diagnostic workup for canine lymphoma (Regan et al., 2013). Thus, strategies to quantify 278 
proliferation rate have been adapted to lymph node aspirates: AgNOR count can be performed with 279 
silver stain on cytological smears (Bauer et al., 2007), and Ki67 expression can be quantified either 280 
by immunostaining of cytological smears (Bauer et al., 2007) or by FC (Poggi et al., 2015). 281 
Until now, DNA content in canine lymphoma has been analysed in one study only, on frozen tissue 282 
samples (Teske et al., 1993). In the present study, we used LN aspirates suspended in a liquid 283 
medium. This makes the examination more feasible for routine clinical practice, as surgical 284 
approach is not required. The opportunity of analysing different parameters on thousands of cells 285 
simultaneously, in face of a minimally invasive sampling procedure, is one of the major advantages 286 
of FC, and partially explains its wide spread in veterinary oncology (Burkhard and Bienzle, 2015; 287 
Comazzi and Gelain, 2011). FC has been used also to assess Ki67 expression in canine lymphomas, 288 
thus allowing a rapid and objective evaluation of the proliferative activity in a large number of cells 289 
(Poggi et al., 2015). Unfortunately, storage of the samples for few days can affect the results of this 290 
analysis (Sun et al., 2016). The technique presented in the present study fills this gap, as it combines 291 
the pros of FC (minimal invasiveness, rapidity, number of cells analysed) with the possible use of 292 
stored material from LN aspirates. Still, the analysis of Ki67 expression should be preferred 293 
whenever possible, as a relevant percentage of samples have to be excluded from DNA content 294 
analysis due to poor sample quality: we had to discard about 10% of the samples due to BAD>20% 295 
or CV>8%. 296 
Based on our results, SPF accurately discriminates between high- and low-grade lymphomas in 297 
dogs. This is in contrast with the results obtained by Teske and colleagues (1993), who failed to 298 
detect any association between SPF and lymphoma malignancy. The difference in the samples used 299 
between the two studies (frozen tissues vs fresh nodalLN aspirates) may partially explain this 300 
discrepancy, as well as the different classification schemes applied. In particular, the WF scheme 301 
includes three grades while only the low and high grade are described in the Kiupelupdated Kiel 302 
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scheme. Most of the cases in the study by Teske and colleagues were allocated exactly in the 303 
intermediate grade, which is not considered not provided for in the Kiel classification used in our 304 
study. Furthermore, Teske and colleagues did not stratify cases according to the neoplastic cells 305 
phenotype when analysing SPF data. 306 
Furthermore, Teske and colleagues determined the B- vs T-cell lineage but they did not considered 307 
it for the classification. Cell lineage was detected only in a part of the tumors and a very different 308 
antibody panel was used. 309 
In line with Teske and colleagues (1993), we found no prognostic significance for SPF. Different 310 
reasons may account for this lack of significant results in the two studies. Teske and colleagues 311 
included in the survival analysis many different lymphoma subtypes, irrespective of the phenotype 312 
and the malignancy grade. In order to avoid this bias, we restricted our analysis to high-grade B-cell 313 
lymphoma cases that underwent a standardized chemotherapy protocol. Unfortunately, only 33 dogs 314 
corresponded to these inclusion criteria, and about one third of them was censored for LSS analysis. 315 
Therefore, our results may be affected by a low statistical power and caution should be used when 316 
considering them. This may explain the lack of significant results for LSS among Ki67 expression 317 
groups, as the median values are in line with what previously reported by our research group (Poggi 318 
et al., 2017). This is also true for the significant results obtained for sex, which may be over-319 
estimated: female dogs have a lower risk to develop lymphoma (Villamil et al., 2009) but to date a 320 
prognostic impact of male versus female sex has never been reported in dogs with lymphoma. 321 
Further studies are warranted, including a larger standardized case series. 322 
SPF was strongly correlated with Ki67 expression in our cases series.  but if bBoth parameters 323 
allow a reliable discrimination between high- and low- grade lymphomas, but survival analyses 324 
gave significant results only for the latter. The difference in the information provided by the two 325 
techniques may account for this: all proliferating cells stain positive for Ki67, whereas only the 326 
subset of cells in the S-phase of the cell cycle are counted with DNA content analysis. In addition, 327 
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the SPF cut-offs we selected may be unsuitable to discriminate different prognostic groups, and 328 
other values may work better.  329 
Even though both analyses (Ki67 and DNA content) can be run in a routine panel for canine 330 
lymphoma diagnosis, in our experience Ki67 determination is currently the first choice because of 331 
the limitations of SPF and ploidy as prognostic markers. Furthermore, the protocol for Ki67 332 
determination is common to all intracytoplasmic labelling (it can easily be run beside the 333 
immunophenotyping analysis) and does not use hazardous reagents such as propidium iodide. SPF 334 
remains an excellent second option in the case the analysis must be delayed. 335 
 336 
Contrasting results have been obtained also in human medicine about the clinical usefulness of 337 
DNA content analysis for non-Hodgkin’s lymphomas: some studies claim for a prognostic value of 338 
SPF and/or ploidy status (Joensuu et al., 1991; Lackowska et al., 1999; Pinto et al., 2003; Rehn et 339 
al., 1990) whereas other authors downsize this hypothesis (Winter et al., 1996). A more recent study 340 
performed on a large case series of human non-Hodgkin’s lymphomas revealed a prognostic impact 341 
for SPF (but not ploidy status) only within specific subtypes (namely, B-cell small lymphocytic 342 
lymphoma, diffuse large B-cell lymphoma and anaplastic large cell lymphoma) (Lackowska et al., 343 
2012): the different inclusion criteria used may therefore account for the different results obtained 344 
in human medicine. Such a detailed study is still lacking for canine lymphoma. 345 
The prevalence of aneuploidy in our case series (6.2%) was lower compared to the one previously 346 
reported in dogs with lymphoma (21.3%) (Teske et al., 1993). This is likely due to the different 347 
criteria used to define aneuploidy. Indeed, we only selected cases were two distinct G0/G1 peaks 348 
were identifiable, whereas Teske and colleagues also included cases with marked asymmetry and 349 
high CV in the G0/G1 peak. This difference particularly affects the possibility to correctly classify 350 
near-diploid cases: samples with DI only slightly >1 may have gone unnoticed in cases with high 351 
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G0/G1 peak CV in our case series, whereas aneuploid cases with higher DI are more easily 352 
detected, irrespective of the CV.  353 
Teske and colleagues (1993) found no prognostic relevance for ploidy status. We did not attempt 354 
such an analysis because of the low number of aneuploid cases. Interestingly, however, a complete 355 
follow up was available for 3 aneuploid T-cell lymphoma cases: the 2 high-grade cases died for 356 
lymphoma after 20 and 70 days, respectively, and the only low-grade case died for lymphoma after 357 
111 days. This is in line with what already reported for dogs with high-grade T-cell lymphomas 358 
(Aresu et al., 2015), whereas dogs with low-grade T-cell lymphoma commonly have a longer 359 
survival (Martini et al 2016; Valli et al., 2013). Further studies including a large cohort of aneuploid 360 
cases with a complete follow up are needed to assess whether ploidy status may affect survival 361 
within specific lymphoma subtypes. 362 
Future investigation should also be aimed at clarify potential diagnostic role of aneuploidy in dogs 363 
with lymphoma. Based on a recent study, indeed, numerical chromosomal aberrations found in the 364 
tumour of dogs with lymphoma are often present also in the peripheral blood. Therefore, the authors 365 
hypothesize the use of peripheral blood as a matrix for cytogenetic analysis to monitor the status of 366 
the disease during treatment (Devitt et al., 2009). Gross numerical chromosomal aberrations may 367 
lead to aneuploidy (Sansregret and Swanton, 2017). If aneuploidy is detected in peripheral blood 368 
from dogs with lymphoma, it may serve as a case-specific tumour fingerprint to assess the minimal 369 
residual disease after treatment. To the authors’ knowledge, however, DNA content in the 370 
peripheral blood from dogs with lymphoma has never been investigated, and these considerations 371 
remain purely speculative. 372 
Even though both analyses can be run in a routine panel for canine lymphoma diagnosis, in our 373 
experience Ki67 determination is currently the first choice because of the limitations of SPF and 374 
ploidy as prognostic markers. Furthermore, the protocol for Ki67 determination is common to all 375 
intracytoplasmic labelling (it can easily be run beside the immunophenotyping analysis) and does 376 
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not use hazardous reagents such as propidium iodide. SPF remains an excellent second option in the 377 
case the analysis must be delayed 378 
The retrospective nature of the present study represents its major limitation, as well as the small 379 
number of aneuploid cases included: these two factors prevented us from performing large-scale 380 
survival analyses and perhaps from identifying a prognostic role for the parameters investigated. In 381 
addition, only lymphoma samples were included in the present study, and the power of SPF to 382 
discriminate between neoplastic and non-neoplastic LNs is still to be elucidated. 383 
In conclusion, DNA content analysis can be of aid to assess the malignancy grade on LN aspirates 384 
from dogs with lymphoma. These data can be combined to the morphological examination to 385 
improve the objectivity in the subtype definition. Identification of the prognostic role of both SPF 386 
and ploidy status requires further studies on a large number of cases.  387 
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Fig.1 Distribution of S-phase fraction values within the four subtypes of lymphoma considered in 525 
the study (high grade B-cell, low grade B-cell, high grade T-cell, and low grade T-cell) 526 
